Dr Yusuf Khwaja Hamied is a polish -born Indian businessperson and Chairman of
Cipla, one of India's largest generic pharmaceutical firms. A PhD from Christ's College, Cambridge, he led from the front in eradicating AIDs and providing inexpensive generic drugs to poorer countries. His love for Chemistry, Cambridge and huge donations to Cambridge resulted in changing the oldest 1702 Chair of Chemistry in his name. Forbes magazine included him in its list of richest Indians with a net worth at US $ 3.3 billion in 2021.

HIS Contribution to Healthcare Landscape in India ;

* Radically lowered the costs of biotech drugs for cancer, diabetes and other non-communicable diseases.
* Developed fixed-dose-combinations-FDCS for HIV/AIDS, TB, asthma and paediatric drugs for developing countries.
* Critical role in "active pharmaceutical ingredients*-APIs in India.
* Was subject of in-depth profiles in world's leading magazines, publications and television outlets like New York Times, The Guardian, Le Monde, Financial Times, BBC, CNN etc.

Change-Making Positions Held ;

* A documentary "Fire in the Blood" portrayed his battle for antiretroviral treatment in Africa for which India Today recognised him as "the only man to walk against the tide and sell drugs to save lives without focusing on profits
* Elected Fellow of Indian Science Academy.
* Popularity known as 'Modern-Day Robin Hood*

Laurels Brought to Dr Yusuf Khwaja ;

* Conferred Padma Bhushan by the Government of India in 2005.
* Harvard Business School and CNN-IBN Indian of 2012 Award.
* One of India's "25 Greatest Global Living Legends" by NDTV in 2013.

Impact Brought in the Lives of Common Indians ;

He "electrified the global health community a decade ago by saying to produce cocktails of AIDs medicine for $1 per day" in the words of New York Times. His no-profit attitude is providing treatment to more than six million people in the developing world, up from little more than 2000 in 2001. A generic version of Remdesivir was launched by Cipla to treat Covid- 19 in 2020.